Patents by Inventor Linda Popplewell
Linda Popplewell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230391840Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.Type: ApplicationFiled: June 21, 2023Publication date: December 7, 2023Inventors: John George Dickson, Linda Popplewell
-
Patent number: 11725032Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.Type: GrantFiled: December 5, 2018Date of Patent: August 15, 2023Assignee: Royal Holloway And Bedford New CollegeInventors: George Dickson, Linda Popplewell
-
Patent number: 11697811Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: January 7, 2021Date of Patent: July 11, 2023Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
-
Patent number: 11624066Abstract: The invention relates to neurodegenerative disorders, and in particular to novel oligonucleotides for treating such conditions, for example Alzheimer's disease. The invention provides novel antisense oligonucleotides, and compositions comprising such oligos, and therapies and methods for treating neurodegenerative disorders. The invention includes genome editing techniques for achieving similar results as using the novel antisense oligonucleotides.Type: GrantFiled: February 25, 2019Date of Patent: April 11, 2023Assignee: Teesside UniversityInventors: Pavlos Alifragis, Linda Popplewell, John George Dickson, Amninder Sangha
-
Publication number: 20230060409Abstract: The present disclosure provides methods and compositions for the treatment of NF-1 and NF-1 mediated conditions. The present disclosure further provides for methods of exon skipping and exon retention and compositions for use in such methods. Such methods of exon skipping and exon retention may be used in the methods of treatment discussed herein. The present disclosure further provides new therapeutic compounds, particularly oligonucleotides, including antisense oligonucleotides, for use in the methods described herein.Type: ApplicationFiled: September 21, 2020Publication date: March 2, 2023Inventors: Deeann WALLIS, Robert KESTERSON, Bruce KORF, Andre LEIER, Laura LAMBERT, Linda POPPLEWELL, George DICKSON
-
Publication number: 20210388353Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: ApplicationFiled: January 7, 2021Publication date: December 16, 2021Inventors: Linda Popplewell, Ian Graham, John George Dickson
-
Publication number: 20210130426Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.Type: ApplicationFiled: December 5, 2018Publication date: May 6, 2021Inventors: George Dickson, Linda Popplewell
-
Publication number: 20210002639Abstract: The invention relates to neurodegenerative disorders, and in particular to novel oligonucleotides for treating such conditions, for example Alzheimer's disease. The invention provides novel antisense oligonucleotides, and compositions comprising such oligos, and therapies and methods for treating neurodegenerative disorders. The invention includes genome editing techniques for achieving similar results as using the novel antisense oligonucleotides.Type: ApplicationFiled: February 25, 2019Publication date: January 7, 2021Inventors: Pavlos Alifragis, Linda Popplewell, George Dickson, Amninder Sangha
-
Patent number: 10457944Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: April 10, 2018Date of Patent: October 29, 2019Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
-
Publication number: 20190112601Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: ApplicationFiled: April 10, 2018Publication date: April 18, 2019Inventors: Linda Popplewell, Ian Graham, John George Dickson
-
Patent number: 9970010Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: March 22, 2017Date of Patent: May 15, 2018Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
-
Publication number: 20170204413Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: ApplicationFiled: March 22, 2017Publication date: July 20, 2017Inventors: Linda Popplewell, Ian Graham, John George Dickson
-
Patent number: 9650632Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: August 24, 2015Date of Patent: May 16, 2017Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
-
Publication number: 20160024500Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: ApplicationFiled: August 24, 2015Publication date: January 28, 2016Inventors: Linda POPPLEWELL, Ian GRAHAM, John George DICKSON
-
Patent number: 9243251Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: June 4, 2013Date of Patent: January 26, 2016Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
-
Patent number: 9243252Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: October 4, 2013Date of Patent: January 26, 2016Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
-
Publication number: 20140057964Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: ApplicationFiled: October 4, 2013Publication date: February 27, 2014Applicant: ROYAL HOLLOWAY, UNIVERSITY OF LONDONInventors: Linda POPPLEWELL, Ian GRAHAM, John George DICKSON
-
Publication number: 20130289096Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: ApplicationFiled: June 4, 2013Publication date: October 31, 2013Inventors: Linda POPPLEWELL, Ian GRAHAM, John George DICKSON
-
Patent number: 8552172Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: November 30, 2011Date of Patent: October 8, 2013Inventors: Linda Popplewell, Ian Graham, John George Dickson
-
Patent number: 8461325Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: November 30, 2011Date of Patent: June 11, 2013Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
